Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González‐Duarte et al.|The Lancet Neurology|2020Cited by 160
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H. Brannagan, Brian Drachman, Peter D. Gorevic et al.|Journal of Neurology|2022Cited by 36
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes SurveyJuan González‐Moreno, Dianna Quan, Angela Dispenzieri et al.|Cardiology and Therapy|2023Cited by 24
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delayTeresa Coelho, Cheng‐Yin Tan, Angela Dispenzieri et al.|Amyloid|2023Cited by 15